<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261727</url>
  </required_header>
  <id_info>
    <org_study_id>TGI-Resp-01</org_study_id>
    <secondary_id>1033117</secondary_id>
    <nct_id>NCT02261727</nct_id>
  </id_info>
  <brief_title>Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study</brief_title>
  <acronym>TASCS</acronym>
  <official_title>Low Dose Corticosteroids and Theophylline in the Treatment of Chronic Obstructive Pulmonary Disease - the TASCS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this multi-centre, double blind, randomised, controlled trial (DBRCT) is to assess
      the effect of low dose theophylline, singly and in combination with low dose oral prednisone,
      on COPD (Chronic Obstructive Pulmonary Disease) exacerbations, quality of life and secondary
      clinical outcomes compared with usual therapy and placebo over 48 weeks of treatment.
      Approximately 2400 symptomatic patients with COPD will be recruited in China for comparison
      of low dose theophylline versus placebo and low dose theophylline + low dose prednisone The
      primary end-point for this study is the difference between the three treatment groups in

        -  COPD exacerbation rate

        -  Time to first severe exacerbation requiring hospitalisation or death
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesise that patients with COPD will have beneficial responses to low
      dose theophylline and prednisone, superior to placebo and low dose theophylline alone,
      reflected by a range of clinical outcomes.

      The study aims to demonstrate that treatment with low dose oral prednisone and low dose, slow
      release theophylline compared to low dose, slow release theophylline only or placebo will
      reduce COPD exacerbations and improve a range of secondary outcomes including quality of
      life, CAT score, hospital admissions and lung function.

      Eligible participants will be randomised to one of three treatment arms in a DBRCT and will
      receive placebo OR low-dose theophylline (100 mg twice a day) OR low-dose theophylline 100 mg
      twice a day (BD) plus low-dose prednisone (5 mg once a day)

      Patients will be eligible for inclusion if all the following criteria are met:

        -  Current or former smokers (&gt;10 pack years) or biomass exposure

        -  40 - 80 years of age

        -  Clinical diagnosis of COPD

        -  Post-bronchodilator forced expiratory volume at one second (FEV1) &lt;70% predicted

        -  Post bronchodilator FEV1/forced vital capacity (FVC) ratio&lt;0.7
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COPD exacerbation rate</measure>
    <time_frame>48 weeks observation; rate annualised</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first COPD exacerbation</measure>
    <time_frame>Time (days) from randomisation to first exacerbationAssessed at weeks 12, 24,36 and 48 using patient diary</time_frame>
    <description>Assessed at weeks 12, 24,36 and 48 using patient diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured by St. George's Respiratory Questionnaire (SGRQ)</measure>
    <time_frame>Change over 48 week study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre and post bronchodilator FEV1</measure>
    <time_frame>Change at 12 week visits and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CAT score</measure>
    <time_frame>12, 24, 36 48 weeks</time_frame>
    <description>COPD Assessment Test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Corticosteroid and theophylline related adverse effects</measure>
    <time_frame>50 weeks</time_frame>
    <description>Adverse effects measured include convulsions, stomach discomfort, headache, insomnia, palpitations, weight gain, bruising. Participants will be specifically asked about respiratory tract infections in the previous 12 weeks and whether bone fractures have occurred. Serum cortisol and adrenocorticotropic hormone (ACTH) suppression tests will be performed to assess adrenal function in a subgroup of 100 patients in arm 2 and 3 at 50 weeks. Serum theophylline will be performed in a subgroup of 100 patients in Arm 2 and 3, at 12 and 48 weeks.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2400</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo theophylline, one tablet twice daily, and Placebo prednisone, one tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose theophylline arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Theophylline 100 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Theophylline and Prednisone arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Theophylline 100 mg twice daily plus prednisone 5 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline</intervention_name>
    <description>Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor</description>
    <arm_group_label>Low-dose theophylline arm</arm_group_label>
    <arm_group_label>Theophylline and Prednisone arm</arm_group_label>
    <other_name>Theophylline (100 mg twice a day)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone is an oral glucocorticosteroid which has anti-inflammatory properties</description>
    <arm_group_label>Theophylline and Prednisone arm</arm_group_label>
    <other_name>Prednisone (5mg once daily)</other_name>
    <other_name>cortisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for prednisone)</intervention_name>
    <description>Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily
Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Low-dose theophylline arm</arm_group_label>
    <other_name>Prednisone placebo 1 tab once daily in arms 1 and 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Theophylline)</intervention_name>
    <description>One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Theophylline placebo 1 tab twice daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current or former smokers (&gt; 10 pack years) or biomass exposure

          -  40 - 80 years of age

          -  Clinical diagnosis of COPD

          -  Post-bronchodilator FEV1 &lt; 70% predicted

          -  Post bronchodilator FEV1/FVC ratio &lt; 0.7

        Exclusion Criteria:

          -  Life expectancy of less than 12 months

          -  Exacerbation or respiratory infection within 4 weeks prior to randomisation

          -  Patient is taking and requires maintenance oral corticosteroids

          -  Patient is on domiciliary oxygen

          -  There has been previous pulmonary resection

          -  Previous sensitivity to, or intolerance of theophylline

          -  Coexistent illness precluding participation in the study (epilepsy, chronic liver
             disease, unstable cardiovascular disease, diabetes, active malignancy)

          -  Inability to complete quality of life questionnaire

          -  Concomitant major illness that would interfere with visits, assessments and follow-up

          -  Have evidence of chronic liver disease, or transaminase or gamma-glutamyltransferase
             (GGT) elevation &gt; 1.5 x upper limit of normal (ULN)

          -  Random blood glucose level &gt; 8mmol/L

          -  High chance in the view of the treating physician that the patient will not adhere to
             study treatment and follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert Berend, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine R Jenkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The George Institute for Global Health</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine R Jenkins, MD</last_name>
      <phone>+61413155111</phone>
      <email>christine.jenkins@sydney.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Allison Humphries, PhD</last_name>
      <phone>+61280524300</phone>
      <email>ahumphries@georgeinstitute.org.au</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Theophylline</keyword>
  <keyword>Oral corticosteroids</keyword>
  <keyword>COPD exacerbations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

